protective efficacy adenovirus/protein vaccines siv challenges rhesus monkeys
preclinical studies viral vector-based hiv vaccine candidates previously shown partial protection neutralization-resistant virus challenges rhesus monkeys study evaluated protective efficacy adenovirus serotype ad26 vector priming followed purified envelope env glycoprotein boosting rhesus monkeys primed ad26 vectors expressing sivsme543 env gag pol boosted as01b-adjuvanted sivmac32h env gp140 demonstrated complete protection % vaccinated animals series repeated heterologous intrarectal sivmac251 challenges infected controls protective efficacy correlated functionality env-specific antibody responses comparable protection also observed similar ad/env vaccine repeated heterologous intrarectal shiv-sf162p3 challenges data demonstrate robust protection ad/env vaccines acquisition neutralization-resistant virus challenges rhesus monkeys
